St Vincent’s Hospital Melbourne plays key role as lead trial site in $2 Million MRFF-Funded BRIDGE-ED project
Posted: 17 February 2026 St Vincent’s Hospital Melbourne (SVHM) is playing a key role as a lead trial site in a pilot research project investigating an intervention aimed at improving health outcomes for people with disabilities who attend…
Monash University and Thermo Fisher Scientific launch Catalyst PhD program
Posted: 17 February 2026 Monash University and Thermo Fisher Scientific have launched the Catalyst PhD program – a new industry partnership designed to apply doctoral-level research skills directly to real-world business challenges. The program was formally launched on…
BHF Technologies develops small-scale ultrafiltration system to address critical water challenges
Posted: 17 February 2026 BHF Technologies has developed its small-scale Ultrafilation (UF) system to address ongoing water quality challenges in healthcare, laboratory and life sciences environments, where safety, compliance and operational reliability are directly affected by water performance.…
Nutromics reports completion of world-first clinical trial of real-time drug monitoring sensor
Posted: 17 February 2026 Nutromics has reported the completion of the world’s first clinical trial of electrochemical aptamer sensors used for the continuous monitoring of a drug molecule in situ in humans. The small-scale clinical trial has evaluated…
BioMelbourne Network Women in Leadership Awards spotlight leadership that crosses boundaries to deliver global impact
Posted: 11 February 2026 Honouring women who drive innovation across Victoria’s health technologies ecosystem. Now in their 11th year, the prestigious BioMelbourne Network Women in Leadership Awards recognise three exceptional leaders advancing health technologies for the benefit of people worldwide. BioMelbourne Network today announces the…
ENA Respiratory announces dosing of first participants in phase II study of INNA-051 Nasal Spray
Posted: 3 February 2026 ENA Respiratory has announced that the first participants have been dosed in its Phase II community study of INNA-051, a nasal spray designed to protect against symptomatic viral respiratory infections. INNA-051 is a virus-agnostic,…
Medicines Development for Global Health commences phase 2 clinical trial of Dovramilast for Leprosy Type 2 reaction
Posted: 3 February 2026 Medicines Development for Global Health (MDGH) has announced, on World Neglected Tropical Disease Day, that its first clinical site has been opened and is ready to begin recruiting participants in a Phase 2 clinical…
AI Mission Statement released by Victorian Government
Posted: 2 February 2026 The Victorian Government has released its AI Mission Statement, setting out a clear plan to responsibly develop and adopt artificial intelligence – harnessing its potential while managing risk. This statement positions Victoria as a…
Cartherics secures second patent in China for TAG-72 CAR gene-modified stem cell technology
Posted: 29 January 2026 Cartherics Pty Ltd has been granted a second patent in China for “Genetically modified cells and uses thereof”, strengthening its intellectual property position for the development of off-the-shelf immune cell therapies focused on high-impact…
Peter MacCallum Cancer Centre awarded more than $7.5 million in NHMRC Ideas Grants to advance cancer research
Posted: 15 January 2026 Peter MacCallum Cancer Centre has been awarded more than $7.5 million through the National Health and Medical Research Council (NHMRC) Ideas Grants, with five projects having been funded to investigate cancer spread, treatment resistance…
Chimeric Therapeutics granted FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
Posted: 8 December 2025 Chimeric Therapeutics Ltd has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for CHM CDH17 in the treatment of gastric cancer. The designation is recognised as a significant milestone…
Cartherics launches spin-out Evinco to advance immune-based therapies for Alzheimer’s disease
Posted: 8 December 2025 Evinco Therapeutics Pty Ltd has been officially launched in Melbourne as a new biotechnology company dedicated to transforming treatments for Alzheimer’s disease and other neuroinflammatory conditions. Based in Melbourne and led by CEO and…
